Introduction
Propionic acidaemia (PA; OMIM #606054) is an autosomal recessive disease that results from propionyl-CoA carboxylase (PCC; EC 6.4.1.3) deficiency (Fenton et al 2001) with an estimated incidence of about 1:50 000 . Affected individuals can have life-threatening episodes of metabolic acidosis with ketosis, hyperammonaemia, or pancytopenia which can result in mental retardation and/or early mortality. In the most severe cases, symptoms such as vomiting, altered mental status, hypotonia, and abnormal movements or seizures can present in the neonatal period. In late-onset disease, patients often present with milder symptoms during an intercurrent illness (Pé rez-Cerdá et al 2000) . Atypical presentations, including acute basal ganglia necrosis (Pé rezCerdá et al 1998) and adult-onset chorea (Sethi et al 1989) , have been observed without documented metabolic acidosis (Nyhan et al 1999) . Rarely do patients present without metabolic acidosis or neurological deficits.
PCC is a biotin-dependent enzyme found in the mitochondrial matrix that is necessary for metabolism of propionate arising from four essential amino acids (isoleucine, valine, threonine and methionine), oddchain fatty acids, and the side-chain of cholesterol, along with other metabolites. Specifically, it catalyses the carboxylation of propionyl-CoA to D-methylmalonylCoA (Fenton et al 2001) . PCC is a dodecameric enzyme composed of six a and six b-subunits (Gravel et al 1980; Kalousek et al 1980) , encoded by PCCA on 13q32 (Kennerknecht et al 1990) and PCCB on 3q13.3-q22 (Kraus et al 1986) . Numerous mutations in PCCA and PCCB have been reported in PA Ugarte et al 1999; Yang et al 2004) .
In this report, we present a 14-year-old male patient with PA who presented with isolated cardiomyopathy without any documented episodes of metabolic acidosis or evidence of any neurocognitive deficits. Biochemical and genetic characterization confirmed a PCC deficiency due to two novel mutations in PCCB, IVS7+2T>G and p.R410Q.
Case presentation
The proband, a 14-year-old male Asian-American with no significant past medical history, was born to nonconsanguineous parents from China. His prenatal, birth, and neonatal history were all unremarkable. He reached all his developmental milestones at an appropriate time and was an honours student in the ninth grade. He was active in school sports such as tennis and swimming. He had no history of myopathy or growth problems. His diet consisted of a traditional Chinese diet with normal protein content.
Several months before presentation, he had progressive exercise intolerance followed by one week of worsening symptoms accompanied by nausea and diarrhoea but did not seek medical attention. On the day of admission, he was found to have an irregular pulse, which on further testing was identified as bigeminy. An echocardiogram showed a markedly dilated left ventricle (interventricular septum in systole 0.81 cm, Z ¼ j2.68 and left ventricular end-diastolic dimension 8.03 cm, Z ¼ 9.42) with severely diminished function and a fractional shortening of 8% (normal 28-40%). The apex of the left ventricle was noted to have trabeculation suggestive of noncompaction (Fig. 1 ). Right ventricular function was also poor. QTc intervals when he was in normal rhythm were all normal and <440 ms.
On physical examination his weight was 55.4 kg (50th-75th centile), and height was 172 cm (75th centile). He had mild jaundice (total bilirubin 4.8 mg/dl; normal 0.30-1.30), icteric sclerae, bilateral rales, an S3 gallop, hepatomegaly 5 cm below the right costal margin, splenomegaly 2 cm below the left costal margin, ascites, and poor peripheral pulses with prolonged capillary refill time >2 seconds. His muscle tone was normal, and no dysmorphic features were noted.
Owing to his poor cardiac function, he was listed and received an orthotopic heart transplant after three days on a paracorporeal biventricular assist device. His posttransplantation course was unremarkable, and he was discharged home 10 days after receiving his transplant. The pathology on the explanted heart showed marked gross hypertrophy of the left ventricle (left ventricle thickness 1.9 cm) with endocardial thickening. Sections from the left ventricle showed moderate to marked hypertrophy of myocytes and scant interstitial fibrosis (Fig. 2) that did not suggest a specific aetiology. Incidental findings included focal injury related to assist device placement and a mild hypersensitivity-type myocarditis.
On metabolic screening as part of his cardiomyopathy evaluation, the patient was found to have abnormal urine organic acids with elevated methylcitric acid and trace amounts of tiglylglycine suggestive of PA. One pre-transplantation and four post-transplantation urine samples all demonstrated similar findings. Concurrent plasma acylcarnitine testing showed marked elevation of propionylcarnitine (20.70 mmol/L; normal <0.83). Free carnitine was normal (50 mmol/L; normal 22-63). Glycine levels were never elevated on plasma amino acid testing (248 mmol/L; normal 127-341). Alanine and branched-chain amino acids were also normal. Given the unusual clinical presentation, he was evaluated for a vitamin B 12 deficiency, but B 12 levels were normal (867 pg/ml; normal 279-996), homocysteine was low (4.3 mmol/L; normal 5.6-13.4 3), and serum methylmalonic acid was normal (0.14 mmol/L; normal 0-0.4).
Enzymatic analysis of lymphocytes demonstrated low PCC activity (12.8 and 15 pmol/min per mg protein on two occasions; normal Q70). Activity of 3-methylcrotonyl-CoA carboxylase was also slightly low (19 and 23.4 pmol/min per mg protein on two occasions; normal Q31) but since there were no other clinical data to support a diagnosis of 3-MCC deficiency, no mutational analysis was attempted. Concurrent analysis of pyruvate carboxylase activity was normal.
Following the diagnosis in the proband, his two brothers, ages 12 and 10 years, were evaluated. Urine organic acid testing and cardiac evaluation were normal in both brothers.
After cardiac transplantation, the patient has done well and has returned to most of his normal activities. He has been maintained on a low-protein diet with supplemental carnitine and biotin. Routine serum chemistry has not revealed any evidence of metabolic acidosis.
Results and discussion
Sequence analysis revealed two novel mutations in PCCB: an intron 7 splice site mutation, IVS7+2T>G (c.763+2T>G) and a missense mutation in exon 12, p. R410Q (c.1229G>A) (Fig. 3) . Results were verified bidirectionally. Mutations at amino acid residue 410 in PCCB disrupt an MspI site. We screened 210 chromosomes from Asian normal controls and identified no carriers for the R410Q variant. Sequencing for PCCA was normal.
The IVS7+2T>G variant occurs at a conserved splice site Richard et al 1997) that would be predicted to lead to exon skipping. Splicing mutations often result in a milder phenotype as these mutations may still produce small amounts of normal Fig. 2 Haematoxylin and eosin stain showing myocardium with myocyte hypertrophy and scant interstitial fibrosis demonstrating non-specific findings of cardiomyopathy protein product . The p.R410Q mutation occurs at the same residue as the known p. R410W mutation which has been reported in different ethnic backgrounds (Gravel et al 1994; Tahara et al 1993; Yang et al 2004) . This mutation has been shown to have partial residual activity in expression analyses (Pé rez-Cerdá et al 2003).
Our patient is atypical in that he had been completely asymptomatic without any documented metabolic decompensation prior to hospitalization. However, given the lack of previous laboratory data, we do not know if he had unrecognized metabolic acidosis in the past. There is a similar report of a 15-year-old boy who also presented with isolated cardiomyopathy and underwent cardiac transplantation (Rhead et al 2007) .
There is heterogeneity in PA disease manifestations. Some studies have reported some individuals without metabolic decompensation (Sass et al 2004) . In addition, with the expansion of newborn screening, more patients with minimal or no clinical manifestations may be identified (Deodato et al 2006; Yorifuji et al 2002) .
Cardiomyopathies are known to be associated with inborn errors of metabolism such as mitochondrial disorders, fatty acid oxidation defects, carnitine deficiency, and glycogen storage diseases. However, there are only a few reports of cardiomyopathy associated with organic acidaemias (Massoud and Leonard 1993) .
The exact pathophysiology of cardiomyopathy in PA is unclear although we and others hypothesize that it is from altered energy metabolism in the cardiac tissue. In one report, low free and total carnitine levels were found in the heart tissue although serum levels were normal (Mardach et al 2005) . In addition, there was a secondary deficiency of respiratory chain complex I observed in the cardiac tissue. Non-compaction cardiomyopathy, which was observed in our patient, has been described in other inherited cardiomyopathies affecting mitochondrial function such as Barth syndrome and may be a sign of altered metabolism in cardiac tissue in contrast to the hypothesis of an arrest of fetal myocardial development in many other nonmetabolic cases.
Recently, electrophysiological disturbances have also been recognized in patients with PA (Kakavand et al 2006) . Baumgartner et al examined 10 patients with PA and found that the QTc was >440 ms in 70% of the patients after early childhood (Baumgartner et al 2007) . This finding raises another important point as it suggests that metabolic patients may have cardiac electrical disturbances that can lead to life-threatening complications if not recognized and treated.
Our patient was quickly listed for cardiac transplantation due to the urgency of his poor cardiac status; his metabolic diagnosis was not made until after his cardiac transplantation. However, this case raises the issues of cardiac versus cardiac and liver transplantation as only liver transplantation is considered curative. Accumulated cases have shown that liver transplantation not only leads to clinical improvement but may also prevent the progression of other sequelae (Barshes et al 2006) .
In summary, we believe that our case demonstrates the utility of metabolic evaluation in cardiomyopathy cases. Fig. 3 Electropherograms of PCCB mutations with sequence shown above and wild-type sequence below for reference. (A) The IVS7+2 mutation results in a T-to-G change 2 bp after exon 7 and is predicted to affect splicing. (B) The p.R410Q (c.1229 G>A) mutation in exon 12 is a highly conserved amino acid
